CARLSBAD, Calif.--(BUSINESS WIRE)--ETI today reported on two pre-clinical studies demonstrating that its intradermal extended release Ropivacaine gel formulation (ETI-211) has a markedly improved safety and pharmacokinetic (PK) profile when compared to the currently marketed ropivacaine solution formulation.
